Santhera Pharmaceuticals Holding AG (0QN1.L) LSE
15.40
-0.7089(-4.40%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
15.40
-0.7089(-4.40%)
Currency In CHF
Address
Hohenrainstrasse 24
Pratteln, 4133
Switzerland
Phone
41 61 906 89 50
Website
Sector
Healthcare
Industry
Biotechnology
Employees
78
First IPO Date
March 06, 2014
| Name | Title | Pay | Year Born |
| Dario Eklund | Chief Executive Officer | 1.23M | 1968 |
| Thomas Meier | Founder & Chairman | 200,000 | 1962 |
| Oliver Kronenberg | Chief Legal Officer & Corporate Secretary | 0 | 1968 |
| Neville Kodkani | Head of Global Marketing & Partner Management | 0 | N/A |
| Andreas Missy | Executive Vice President of Corporate Planning & Business Development | 0 | N/A |
| Shabir Hasham | Chief Medical Officer | 0 | 1970 |
| Catherine Ann Isted | Chief Financial Officer | 0 | 1975 |
| Sarah Holmes-Klotz | Global Head of People & Culture | 0 | N/A |
| Marc Schrader | Chief Technology Officer | 0 | 1971 |
| Oliver Strub | Head of Compliance | 0 | 1963 |
| Geert Jan van Daal | Chief Commercial Officer | 0 | 1960 |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.